Non-Statin Lipid Drugs: Ezetimibe, PCSK9 Inhibitors & Fibrates
Some people are born with cholesterol so high that even the strongest statin barely dents it — and for them, and for the millions who can't tolerate statins, a whole toolkit of other drugs exists. One injection can slash cholesterol by blocking a single protein your liver makes to sabotage itself. Others target a completely different fat — triglycerides — that statins barely touch. Here's the rest of the lipid pharmacy.
A young woman has sky-high LDL cholesterol despite a perfect diet and the maximum dose of a powerful statin — she has an inherited condition (familial hypercholesterolaemia) that floods her blood with cholesterol. Her doctor adds a newer injectable drug, and her LDL plummets by more than half. The drug works by blocking a single protein her liver makes that normally destroys its own cholesterol-clearing receptors. When statins aren't enough — or can't be taken — this is the world of drugs that opens up.
The LDL-lowering add-ons
Several drugs lower LDL by other routes. Ezetimibe blocks the absorption of cholesterol from the gut (via a transporter called NPC1L1), giving a modest extra LDL drop — it's the usual first add-on when a statin alone isn't enough. The heavy hitters are the PCSK9 inhibitors (evolocumab, alirocumab), injectable antibodies that block a protein called PCSK9. Normally PCSK9 destroys the liver's LDL receptors; block it, and the liver keeps far more receptors to vacuum LDL out of the blood — producing dramatic reductions, ideal for familial hypercholesterolaemia and very high-risk patients (they're powerful but expensive). Bempedoic acid works upstream of the statin's enzyme and, because it's activated mainly in the liver, causes less muscle trouble — useful in statin-intolerant patients. And bile acid sequestrants (cholestyramine) bind bile acids in the gut, forcing the liver to burn cholesterol to make more — lowering LDL, at the cost of bloating and interfering with the absorption of other drugs.
The triglyceride drugs
Not all blood fat is LDL. Triglycerides are a different lipid, and very high levels bring their own risk (including pancreatitis) — and statins barely lower them. Fibrates (fenofibrate, gemfibrozil) are the main triglyceride-lowering drugs; they activate a receptor (PPAR-alpha) that ramps up fat breakdown, cutting triglycerides and modestly raising 'good' HDL. Their caution: combining a fibrate with a statin — especially gemfibrozil — raises the risk of muscle damage, and they can cause gallstones. Omega-3 fatty acids (like icosapent ethyl) also lower triglycerides. And niacin lowers LDL and triglycerides and raises HDL, but its bothersome flushing (a prostaglandin effect eased by aspirin) and metabolic side effects have pushed it out of routine use. The rule of thumb: statins (± ezetimibe/PCSK9) for LDL, fibrates/omega-3 for high triglycerides.
PCSK9 is a beautiful example of turning a genetic discovery into a drug. Scientists noticed that people born with a broken PCSK9 gene had lifelong low LDL and almost no heart disease — because without PCSK9, their livers kept extra LDL receptors. So a drug that BLOCKS PCSK9 mimics that lucky mutation, producing huge LDL reductions. It's precision medicine written from human genetics: find the gene that protects, and build a drug that copies it.
- Ezetimibe blocks gut cholesterol absorption (NPC1L1) — a modest LDL add-on.
- PCSK9 inhibitors (evolocumab) block PCSK9 → more LDL receptors → big LDL drop (injectable).
- Bile acid sequestrants lower LDL; bempedoic acid helps statin-intolerant patients.
- Fibrates & omega-3 mainly lower TRIGLYCERIDES; fibrate + statin raises muscle risk.
- Rule of thumb: statins for LDL, fibrates/omega-3 for high triglycerides.
- Combining gemfibrozil with a statin. It sharply raises the risk of myopathy.
- Using a fibrate to lower LDL. Fibrates mainly target triglycerides.
- Giving other oral drugs with a bile acid sequestrant. It blocks their absorption.
- Forgetting very high triglycerides risk pancreatitis, not just heart disease.
A PCSK9 inhibitor lowers LDL by:
- Ezetimibe (gut absorption) and PCSK9 inhibitors (more LDL receptors) add to statins for LDL.
- PCSK9 inhibitors give big LDL drops — for familial/very-high-risk; bempedoic acid suits statin-intolerance.
- Fibrates & omega-3 mainly lower triglycerides; fibrate + statin raises muscle risk.
- Statins for LDL, fibrates/omega-3 for high triglycerides; raising HDL is no longer a target.
- Katzung BG. Basic & Clinical Pharmacology — Agents Used in Dyslipidemia (ezetimibe, PCSK9, fibrates, niacin).
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Drug therapy for dyslipidemias.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Lipoprotein metabolism & lipid-lowering drugs.
- ACC/AHA & ESC/EAS Cholesterol Guidelines — Non-statin therapies & PCSK9 inhibitors.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Non-statin lipid-lowering drugs.
